Klotho Neurosciences (KLTO) CFO receives 2.5M-share equity grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.
Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
LeBlanc Jeff
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,500,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 3,420,342 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did KLTO report for CFO Jeff LeBlanc?
Klotho Neurosciences reported that CFO Jeff LeBlanc received a grant of 2,500,000 shares of common stock. The award was issued at $0.00 per share under the company’s Equity Incentive Plan, increasing his directly held ownership stake.
What is the transaction code used in the KLTO Form 4 for the CFO grant?
The transaction code is “A,” indicating a grant, award, or other acquisition. This shows the 2,500,000 Klotho Neurosciences common shares were received as an equity award, consistent with the company’s Equity Incentive Plan footnote disclosure.
What type of security did the KLTO CFO receive in this insider filing?
CFO Jeff LeBlanc received Klotho Neurosciences common stock. The Form 4 reports a non-derivative transaction involving 2,500,000 shares of common stock granted under the company’s Equity Incentive Plan, increasing his directly owned share position.